PANACHE01

Arndt Vogel: Neratinib alone has no effect, but are the combinations promising?

Arndt Vogel, Director of the Center for Personalized Medicine at Hannover Medical School, shared a post on X about recent paper by Ghassan K. Abou-Alfa et al.:

“Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without mTOR Inhibitors in Fibrolamellar Carcinoma Liver Cancer

Not sure what to conclude… Neratinib alone has no effect, but are the combinations promising?”

Authors: Ghassan K. Abou-Alfa et al.

Arndt Vogel

Albert S. Cornelius Alison Clemens O'Neill Amin Yaqubie Arndt Vogel cancer Crystal S. Denlinger Daniel DiPrimeo David B. Solit Eileen M. O'Reilly fibrolamellar carcinoma Ghassan K. Abou-Alfa James J. Harding John D. Gordan Joseph S. Light Lisa D. Eli liver cancer OncoDaily Oncology Pablo Cano Raed Al-Rajabi Richard Kinh Gian Do Sarina A Piha-Paul Scott Sherrin Tim Meyer